Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NVP-BVU972 是 Met 选择性抑制剂 (IC50:14 nM) ,它对其它的激酶抑制性较低。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 528 | 现货 | ||
2 mg | ¥ 777 | 现货 | ||
5 mg | ¥ 1,330 | 现货 | ||
10 mg | ¥ 1,970 | 现货 | ||
25 mg | ¥ 3,810 | 现货 | ||
50 mg | ¥ 5,470 | 现货 | ||
100 mg | ¥ 7,670 | 现货 | ||
500 mg | ¥ 15,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,460 | 现货 |
产品描述 | NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM. |
靶点活性 | MET:14 nM |
体内活性 | NVP-BVU972有效抑制MET基因扩散的细胞系GTL-16,MKN-45和EBC-1的生长,IC50分别为66,82和32 nM。NVP-BVU972有效抑制MET激酶,而对其他激酶(包括最密切相关的激酶)RON抑制作用很低,IC50>1000 nM。NVP-BVU972抑制GTL-16细胞中组成型MET磷酸化,抑制A549细胞中HGF刺激的MET磷酸化,IC50分别为7.3和 22 nM。NVP-BVU972作用于表达野生型TPR-MET的BaF3细胞,剂量依赖性降低TPR-MET磷酸化。 |
激酶实验 | TR-FRET biochemical assay with MET wild type and mutants: Enzyme activity is measured in a time resolved fluorescence resonance energy transfer (TR-FRET) assay, detecting tyrosine phosphorylation with a Eu-labelled anti-phospho-tyrosine antibody (fluorescence donor) and Allophycocyanin conjugated to Streptavidin (fluorescence acceptor) which binds to a biotin on the substrate peptide. For each variant, Km concentrations for ATP are determined in the absence of NVP-BVU972, and the ATP concentration in the kinase reaction is set to Km (4 μM for MET wt, 1 μM for MET Y1230H and MET F1200I). NVP-BVU972 is dissolved and diluted in DMSO and assayed in quadruplicate. Kinase reactions are carried out in 50 mM Tris-HCl pH 7.5, 8 mM MgCl2, 4 mM MnCl2, 0.05 % Tween 20, 0.05% bovine serum albumin, 0.1 mM EDTA, 1 mM DTT, 0.1 mM Na3VO4, in white 1536 well plates at room temperature. NVP-BVU972 and enzyme are incubated in a volume of 2 μL for 20 min, followed by the addition of 1 μL ATP and 1 μL biotinylated peptide substrate (PTK1) to final concentrations of Km and 1 μM, respectively. Enzyme concentrations in the reactions are 5 nM for MET wt, and 4 nM for the F1200I and Y1230H variants. After 90 min, reactions are stopped by addition of 1 μL stop/detection solution to reach final concentrations of 10 mM EDTA, 3.5 nM Eu-labelled antiphospho-tyrosine antibody PY20, and 10 nM Streptavidin Allophycocyanin. Time resolved fluorescence resonance energy transfer is measured in an Envision plate reader (excitation 320 nm, emission 615 nm and 665 nm). |
细胞实验 | BaF3 cells containing TPR-MET or various mutants thereof are grown in RPMI 1640 medium containing 10% fetal calf serum. For maintenance of parental BaF3 cells the medium is additionally supplemented with 10 ng/mL interleukin-3 (IL-3). For proliferation assays, BaF3 cells are seeded on 96-well-plates in triplicates at 104 cells per well and incubated with various concentrations of NVP-BVU972 for 72 hours followed by quantification of viable cells using a resazurin sodium salt dye reduction readout. IC50 values are determined with the XLFit Excel Add-In using a 4-parameter dose response model.(Only for Reference) |
分子量 | 340.38 |
分子式 | C20H16N6 |
CAS No. | 1185763-69-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 63 mg/mL (185.1 mM)
Ethanol: 63 mg/mL (185.1 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.9379 mL | 14.6895 mL | 29.3789 mL | 73.4473 mL |
5 mM | 0.5876 mL | 2.9379 mL | 5.8758 mL | 14.6895 mL | |
10 mM | 0.2938 mL | 1.4689 mL | 2.9379 mL | 7.3447 mL | |
20 mM | 0.1469 mL | 0.7345 mL | 1.4689 mL | 3.6724 mL | |
50 mM | 0.0588 mL | 0.2938 mL | 0.5876 mL | 1.4689 mL | |
100 mM | 0.0294 mL | 0.1469 mL | 0.2938 mL | 0.7345 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
NVP-BVU972 1185763-69-2 Tyrosine Kinase/Adaptors c-Met/HGFR inhibit NVP-BVU 972 BaF3 TPR-MET phosphorylation cancer BaF3 anti-proliferation MET resistance mutations Inhibitor NVP-BVU-972 NVP BVU972 NVPBVU972 inhibitor